BioSig Places Second PURE EP™ System For Evaluation at Cleveland Clinic a Leading Medical Center of Excellence
August 24 2022 - 9:17AM
- Leading Medical Center of Excellence adds second PURE
EP™ System for evaluation, broadening physician access to the
Company’s signal processing technology
- PURE EP™ is now being evaluated at both Main and
Fairview campuses of Cleveland Clinic’s Heart, Vascular &
Thoracic Institute
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the
"Company"), a medical technology company advancing
electrophysiology workflow by delivering greater intracardiac
signal fidelity through its proprietary signal processing platform,
today announced that it has installed a second evaluation system at
the Cleveland Clinic. The additional installation will support the
medical center’s clinical evaluation of the PURE EP™ System and
expand physician access to the Company’s signal processing
technology.
“I am pleased to see the growing interest and demand for our
technology at The Cleveland Clinic. The additional unit will enable
more physicians the opportunity to experience the superior signal
quality of the PURE EP™ System on a broad range of cases.”
commented Gray Fleming, Chief Commercialization Officer, BioSig
Technologies, Inc.
Consistent with its stated national commercial strategy, the
Company’s customer-centered approach aims to maximize the clinical
value and deployment of the PURE EP™ System which has gained
interest in several electrophysiology labs in the Midwest. The
Company recently expanded its clinical footprint in Illinois with
an additional evaluation agreement at a leading medical center in
Springfield, the state capital.
Looking ahead, BioSig will serve as a partner at the upcoming
Cleveland Clinic Global EP Summit 2022, due to take place this
coming September. This annual forum convenes over 40 global experts
and highlights the latest practice insights across the spectrum of
electrophysiology care.
About Cleveland Clinic
Cleveland Clinic is a nonprofit multispecialty academic medical
center that integrates clinical and hospital care with research and
education. U.S. News & World Report consistently names
Cleveland Clinic as one of the nation’s best hospitals in its
annual “America’s Best Hospitals” survey. As a leader in arrhythmia
treatment and diagnosis, Cleveland Clinic medical centers include
state-of-the-art electrophysiology laboratories, world-class
physicians and researchers, and the latest cutting-edge
technologies and protocols deployed for the treatment of heart
abnormalities. To learn more, visit clevelandclinic.org.
About BioSig Technologies
BioSig Technologies is a medical technology company
commercializing a proprietary biomedical signal processing platform
designed to improve signal fidelity and uncover the full range of
ECG and intra-cardiac signals (www.biosig.com).
The Company's first product, PURE EP™ System, is a novel signal
processing and acquisition platform designed to extract advanced
diagnostic and therapeutic data that enhances physician workflow
and increases throughput. PURE EP™ was engineered to address the
limitations of existing EP technologies by empowering physicians
with superior signals and actionable insights. The Company is in a
national commercial launch of the PURE EP™ System. The technology
is in regular use in some of the country’s leading centers of
excellence, including Mayo Clinic, and Texas Cardiac Arrhythmia
Institute at St. David’s Medical Center.
Clinical data acquired by the PURE EP™ System in a multi-center
study at centers of excellence including Texas Cardiac Arrhythmia
Institute at St. David’s Medical Center was recently
published in the Journal of Cardiovascular Electrophysiology and is
available electronically with open access via the Wiley Online
Library. Study results showed 93% consensus across the blinded
reviewers with a 75% overall improvement in intracardiac signal
quality and confidence in interpreting PURE EP(T.M.) signals over
conventional sources.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) market conditions and the
Company’s intended use of proceeds, (ii) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (iii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iv)
difficulties in obtaining financing on commercially reasonable
terms; (v) changes in the size and nature of our competition; (vi)
loss of one or more key executives or scientists; and (vii)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024